REVOLUTION MEDICINES, INC.
REVOLUTION MEDICINES, INC. (RVMD): 19 pipeline candidates · 7 upcoming catalysts · ~16 mo cash runway · 16 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
15.7 months
D/E 0.50 · 0% dilution
Lead: Phase 3
19 candidates
7 upcoming, next in ~531d
0 buys · 38 sells (180d)
A transparent, data-derived signal for REVOLUTION MEDICINES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$34.2B
Cash
$445.8M
Quarterly Burn
$354.2M
Runway
15.7 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (19 candidates)
| Drug | Phase |
|---|---|
| cetuximab | Phase 1/Phase 2 |
| daraxonrasib | Phase 3 |
| elironrasib | Phase 3 |
| ivonescimab | Phase 1/Phase 2 |
| leucovorin | Phase 3 |
| mfolfirinox regimen | Phase 1/Phase 2 |
| mfolfox6 regimen | Phase 1/Phase 2 |
| pemetrexed | Phase 1/Phase 2 |
| rmc-0708 | Preclinical |
| rmc-4630 | Phase 3 |
Showing 10 of 19 candidates. Sign up for full pipeline.
Upcoming Catalysts (7)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
516
Total value held
$20.02B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 19,532,992 | $1.90B |
| vanguard capital management llc | 16,724,568 | $1.63B |
| farallon capital management llc | 13,604,796 | $1.32B |
| blackrock, inc. | 11,212,706 | $1.09B |
| baker bros. advisors lp | 9,555,357 | $929.3M |
| fmr llc | 8,464,314 | $823.2M |
| vanguard portfolio management llc | 7,502,623 | $729.6M |
| wellington management group llp | 6,027,819 | $586.2M |
| adage capital partners gp, l.l.c. | 5,475,611 | $532.5M |
| woodline partners lp | 5,013,140 | $487.5M |
Showing top 10 of 516 institutional holders of REVOLUTION MEDICINES, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in REVOLUTION MEDICINES, INC.'s pipeline?
REVOLUTION MEDICINES, INC. (RVMD) has 19 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is REVOLUTION MEDICINES, INC.'s lead drug candidate?
REVOLUTION MEDICINES, INC.'s most advanced tracked candidate is cetuximab (Phase 1/Phase 2) for Non-small Cell Lung Cancer (NSCLC); Advanced Solid Tumors; Colorectal Cancer.
What is REVOLUTION MEDICINES, INC.'s next catalyst?
REVOLUTION MEDICINES, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus " — expected December 1, 2027.
What is REVOLUTION MEDICINES, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, REVOLUTION MEDICINES, INC. has approximately 15.7 months of cash runway.
What is REVOLUTION MEDICINES, INC.'s market capitalization?
REVOLUTION MEDICINES, INC.'s market capitalization is approximately $34.2B.
Get the full picture on REVOLUTION MEDICINES, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.